Vertex Pharmaceuticals Inc VRTX

Vertex Pharmaceuticals Incorporated es una empresa de biotecnología. La compañía se enfoca en desarrollar y comercializar terapias para el tratamiento de la fibrosis quística (CF) y en avanzar en sus programas de investigación y desarrollo en otras indicaciones. Los medicamentos comercializados por la compañía son TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI y KALYDECO. Ofrece sus productos para tratar a personas con CF que tienen mutaciones específicas en su gen regulador de la conductancia transmembrana de la fibrosis quística (CFTR). Sus correctores de CFTR, como lumacaftor, tezacaftor y elexacaftor, ayudan a que las proteínas CFTR lleguen a la superficie celular. Ofrece una cartera de medicamentos de moléculas pequeñas en otras enfermedades graves en las que tiene conocimientos sobre la biología humana causal, incluyendo el dolor, la deficiencia de alfa-1 antitripsina y las enfermedades renales mediadas por APOL1.

• Zacks Investment Research 1 oct

  Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know

  Vertex Pharmaceuticals stock declined 3.07% to $506.74 on October 1, 2026, underperforming the broader market gains. Despite positive earnings forecasts with expected EPS growth of 1.25% and revenue growth of 10.43% for the upcoming quarter, the stock has fallen 6.1% over the past month. The company holds a Zacks Rank of #3 (Hold) with a Forward P/E ratio of 27.73, trading at a premium to its industry average.

  

• Zacks Investment Research 23 sept

  Vertex Posts Positive Phase II Data on Kidney Disease Drug

  Vertex Pharmaceuticals reported positive results from its phase IIb AMPLIFIED study, showing that inaxaplin reduced UACR by 42.7% in AMKD patients with modest proteinuria and 17.3% in those with AMKD and type II diabetes. The company has completed enrollment in the phase II/III AMPLITUDE pivotal study, with interim data expected in early 2027. Inaxaplin was well-tolerated with no serious adverse events reported.

  

• The Motley Fool 22 sept

  Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH

  The Invesco Nasdaq Biotechnology ETF (IBBQ) offers lower costs (0.19% expense ratio) and higher 1-year returns (44.6%), making it suitable for growth-focused investors willing to accept volatility. The iShares U.S. Healthcare ETF (IYH) provides broader diversification across 100 healthcare holdings with higher dividend yield (1.1%) and lower volatility, appealing to conservative investors seeking stability and income.

  

• GlobeNewswire Inc. 17 sept

  Aerska Appoints Laura Sepp-Lorenzino to Scientific Advisory Board

  Aerska, a biotechnology company developing RNA medicines for CNS diseases through its antibody-oligonucleotide conjugate (AOC) platform, has appointed Laura Sepp-Lorenzino to its Scientific Advisory Board. Sepp-Lorenzino brings over 30 years of experience in genetic medicines and nucleic acid therapies, previously serving as Chief Scientific Officer at Intellia Therapeutics and leading nucleic acid programs at Vertex Pharmaceuticals.

  

• Zacks Investment Research 16 sept

  SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down

  Sionna Therapeutics announced a 46% workforce reduction and major restructuring following the failure of SION-719 to meet its primary endpoint in a cystic fibrosis study. The company is shifting focus to its dual combination therapy SION-451 + SION-2222, which it plans to advance into phase IIa trials in 2027. The restructuring is expected to extend cash runway into the second half of 2029.